Baseline findings of the Italian multicenter randomized controlled trial of "Once-Only Sigmoidoscopy" - SCORE

Nereo Segnan, Carlo Senore, Bruno Andreoni, Hugo Aste, Luigina Bonelli, Cristiano Crosta, Roberto Ferraris, Stefano Gasperoni, Angelo Penna, Mauro Risio, Francesco Paolo Rossini, Stefania Sciallero, Marco Zappa, Wendy S. Atkin

Research output: Contribution to journalArticle

Abstract

Background: A single sigmoidoscopy examination at around age 60 years has been proposed as a cost-effective strategy to prevent colorectal cancer. A multicenter randomized controlled trial, the SCORE trial, is in progress in Italy to estimate the impact of this strategy on colorectal cancer incidence and mortality and the duration of the protective effect. We present the baseline screening outcomes. Methods: A questionnaire was mailed to a random sample of 236 568 people aged 55-64 years to assess their eligibility for and interest in screening. Those reporting a history of colorectal cancer, adenomas, inflammatory bowel disease, recent colorectal endoscopy, or two first-degree relatives with colorectal cancer were excluded. Eligible, interested respondents were assigned randomly to the control group (no further contact) or the intervention group (invitation to undergo sigmoidoscopy). Screenees with colorectal cancer, polyps larger than 5 mm, three or more adenomas, adenomas 5 mm or smaller with a villous component of more than 20%, or severe dysplasia were referred for colonoscopy. Results: Of the 56 532 respondents (23.9 % of those invited), 34 292 were enrolled and 17 148 were assigned to the screening group. Of those, 9999 attended and 9911 were actually examined by sigmoidoscopy. Distal adenomas were detected in 1070 subjects (10.8%). Proximal adenomas were detected in 116 of 747 (15.5%) subjects without cancer at sigmoidoscopy who then underwent colonoscopy. A total of 54 subjects was found to have colorectal cancer, a rate of 5.4 per 1000 (54% of which were Dukes' A). The procedures were relatively safe, with two perforations (one in 9911 sigmoidoscopy exams and one in 775 colonoscopies) and one hemorrhage requiring hospitalization after polypectomy during colonoscopy. The pain associated with sigmoidoscopy was described as mild or less than expected by 83.3% of the screenees. Conclusion: Sigmoidoscopy screening is generally acceptable to recipients and safe. The high yield of advanced adenomas is consistent with the projected impact of sigmoidoscopy screening on colorectal cancer incidence.

Original languageEnglish
Pages (from-to)1763-1772
Number of pages10
JournalJournal of the National Cancer Institute
Volume94
Issue number23
Publication statusPublished - Dec 4 2002

Fingerprint

Sigmoidoscopy
Randomized Controlled Trials
Colorectal Neoplasms
Adenoma
Colonoscopy
Incidence
Polyps
Inflammatory Bowel Diseases
Italy
Endoscopy
Hospitalization
Hemorrhage
Costs and Cost Analysis
Pain
Control Groups
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baseline findings of the Italian multicenter randomized controlled trial of "Once-Only Sigmoidoscopy" - SCORE. / Segnan, Nereo; Senore, Carlo; Andreoni, Bruno; Aste, Hugo; Bonelli, Luigina; Crosta, Cristiano; Ferraris, Roberto; Gasperoni, Stefano; Penna, Angelo; Risio, Mauro; Rossini, Francesco Paolo; Sciallero, Stefania; Zappa, Marco; Atkin, Wendy S.

In: Journal of the National Cancer Institute, Vol. 94, No. 23, 04.12.2002, p. 1763-1772.

Research output: Contribution to journalArticle

Segnan, N, Senore, C, Andreoni, B, Aste, H, Bonelli, L, Crosta, C, Ferraris, R, Gasperoni, S, Penna, A, Risio, M, Rossini, FP, Sciallero, S, Zappa, M & Atkin, WS 2002, 'Baseline findings of the Italian multicenter randomized controlled trial of "Once-Only Sigmoidoscopy" - SCORE', Journal of the National Cancer Institute, vol. 94, no. 23, pp. 1763-1772.
Segnan, Nereo ; Senore, Carlo ; Andreoni, Bruno ; Aste, Hugo ; Bonelli, Luigina ; Crosta, Cristiano ; Ferraris, Roberto ; Gasperoni, Stefano ; Penna, Angelo ; Risio, Mauro ; Rossini, Francesco Paolo ; Sciallero, Stefania ; Zappa, Marco ; Atkin, Wendy S. / Baseline findings of the Italian multicenter randomized controlled trial of "Once-Only Sigmoidoscopy" - SCORE. In: Journal of the National Cancer Institute. 2002 ; Vol. 94, No. 23. pp. 1763-1772.
@article{c6b139428f494578b28407b7f6cc2351,
title = "Baseline findings of the Italian multicenter randomized controlled trial of {"}Once-Only Sigmoidoscopy{"} - SCORE",
abstract = "Background: A single sigmoidoscopy examination at around age 60 years has been proposed as a cost-effective strategy to prevent colorectal cancer. A multicenter randomized controlled trial, the SCORE trial, is in progress in Italy to estimate the impact of this strategy on colorectal cancer incidence and mortality and the duration of the protective effect. We present the baseline screening outcomes. Methods: A questionnaire was mailed to a random sample of 236 568 people aged 55-64 years to assess their eligibility for and interest in screening. Those reporting a history of colorectal cancer, adenomas, inflammatory bowel disease, recent colorectal endoscopy, or two first-degree relatives with colorectal cancer were excluded. Eligible, interested respondents were assigned randomly to the control group (no further contact) or the intervention group (invitation to undergo sigmoidoscopy). Screenees with colorectal cancer, polyps larger than 5 mm, three or more adenomas, adenomas 5 mm or smaller with a villous component of more than 20{\%}, or severe dysplasia were referred for colonoscopy. Results: Of the 56 532 respondents (23.9 {\%} of those invited), 34 292 were enrolled and 17 148 were assigned to the screening group. Of those, 9999 attended and 9911 were actually examined by sigmoidoscopy. Distal adenomas were detected in 1070 subjects (10.8{\%}). Proximal adenomas were detected in 116 of 747 (15.5{\%}) subjects without cancer at sigmoidoscopy who then underwent colonoscopy. A total of 54 subjects was found to have colorectal cancer, a rate of 5.4 per 1000 (54{\%} of which were Dukes' A). The procedures were relatively safe, with two perforations (one in 9911 sigmoidoscopy exams and one in 775 colonoscopies) and one hemorrhage requiring hospitalization after polypectomy during colonoscopy. The pain associated with sigmoidoscopy was described as mild or less than expected by 83.3{\%} of the screenees. Conclusion: Sigmoidoscopy screening is generally acceptable to recipients and safe. The high yield of advanced adenomas is consistent with the projected impact of sigmoidoscopy screening on colorectal cancer incidence.",
author = "Nereo Segnan and Carlo Senore and Bruno Andreoni and Hugo Aste and Luigina Bonelli and Cristiano Crosta and Roberto Ferraris and Stefano Gasperoni and Angelo Penna and Mauro Risio and Rossini, {Francesco Paolo} and Stefania Sciallero and Marco Zappa and Atkin, {Wendy S.}",
year = "2002",
month = "12",
day = "4",
language = "English",
volume = "94",
pages = "1763--1772",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "23",

}

TY - JOUR

T1 - Baseline findings of the Italian multicenter randomized controlled trial of "Once-Only Sigmoidoscopy" - SCORE

AU - Segnan, Nereo

AU - Senore, Carlo

AU - Andreoni, Bruno

AU - Aste, Hugo

AU - Bonelli, Luigina

AU - Crosta, Cristiano

AU - Ferraris, Roberto

AU - Gasperoni, Stefano

AU - Penna, Angelo

AU - Risio, Mauro

AU - Rossini, Francesco Paolo

AU - Sciallero, Stefania

AU - Zappa, Marco

AU - Atkin, Wendy S.

PY - 2002/12/4

Y1 - 2002/12/4

N2 - Background: A single sigmoidoscopy examination at around age 60 years has been proposed as a cost-effective strategy to prevent colorectal cancer. A multicenter randomized controlled trial, the SCORE trial, is in progress in Italy to estimate the impact of this strategy on colorectal cancer incidence and mortality and the duration of the protective effect. We present the baseline screening outcomes. Methods: A questionnaire was mailed to a random sample of 236 568 people aged 55-64 years to assess their eligibility for and interest in screening. Those reporting a history of colorectal cancer, adenomas, inflammatory bowel disease, recent colorectal endoscopy, or two first-degree relatives with colorectal cancer were excluded. Eligible, interested respondents were assigned randomly to the control group (no further contact) or the intervention group (invitation to undergo sigmoidoscopy). Screenees with colorectal cancer, polyps larger than 5 mm, three or more adenomas, adenomas 5 mm or smaller with a villous component of more than 20%, or severe dysplasia were referred for colonoscopy. Results: Of the 56 532 respondents (23.9 % of those invited), 34 292 were enrolled and 17 148 were assigned to the screening group. Of those, 9999 attended and 9911 were actually examined by sigmoidoscopy. Distal adenomas were detected in 1070 subjects (10.8%). Proximal adenomas were detected in 116 of 747 (15.5%) subjects without cancer at sigmoidoscopy who then underwent colonoscopy. A total of 54 subjects was found to have colorectal cancer, a rate of 5.4 per 1000 (54% of which were Dukes' A). The procedures were relatively safe, with two perforations (one in 9911 sigmoidoscopy exams and one in 775 colonoscopies) and one hemorrhage requiring hospitalization after polypectomy during colonoscopy. The pain associated with sigmoidoscopy was described as mild or less than expected by 83.3% of the screenees. Conclusion: Sigmoidoscopy screening is generally acceptable to recipients and safe. The high yield of advanced adenomas is consistent with the projected impact of sigmoidoscopy screening on colorectal cancer incidence.

AB - Background: A single sigmoidoscopy examination at around age 60 years has been proposed as a cost-effective strategy to prevent colorectal cancer. A multicenter randomized controlled trial, the SCORE trial, is in progress in Italy to estimate the impact of this strategy on colorectal cancer incidence and mortality and the duration of the protective effect. We present the baseline screening outcomes. Methods: A questionnaire was mailed to a random sample of 236 568 people aged 55-64 years to assess their eligibility for and interest in screening. Those reporting a history of colorectal cancer, adenomas, inflammatory bowel disease, recent colorectal endoscopy, or two first-degree relatives with colorectal cancer were excluded. Eligible, interested respondents were assigned randomly to the control group (no further contact) or the intervention group (invitation to undergo sigmoidoscopy). Screenees with colorectal cancer, polyps larger than 5 mm, three or more adenomas, adenomas 5 mm or smaller with a villous component of more than 20%, or severe dysplasia were referred for colonoscopy. Results: Of the 56 532 respondents (23.9 % of those invited), 34 292 were enrolled and 17 148 were assigned to the screening group. Of those, 9999 attended and 9911 were actually examined by sigmoidoscopy. Distal adenomas were detected in 1070 subjects (10.8%). Proximal adenomas were detected in 116 of 747 (15.5%) subjects without cancer at sigmoidoscopy who then underwent colonoscopy. A total of 54 subjects was found to have colorectal cancer, a rate of 5.4 per 1000 (54% of which were Dukes' A). The procedures were relatively safe, with two perforations (one in 9911 sigmoidoscopy exams and one in 775 colonoscopies) and one hemorrhage requiring hospitalization after polypectomy during colonoscopy. The pain associated with sigmoidoscopy was described as mild or less than expected by 83.3% of the screenees. Conclusion: Sigmoidoscopy screening is generally acceptable to recipients and safe. The high yield of advanced adenomas is consistent with the projected impact of sigmoidoscopy screening on colorectal cancer incidence.

UR - http://www.scopus.com/inward/record.url?scp=0037021672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037021672&partnerID=8YFLogxK

M3 - Article

C2 - 12464648

AN - SCOPUS:0037021672

VL - 94

SP - 1763

EP - 1772

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 23

ER -